trending Market Intelligence /marketintelligence/en/news-insights/trending/k_VuLmfErGlJcKG3Zpwf5w2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Sapporo Clinical Laboratory fiscal Q2 profit falls YOY

Blog

COVID-19 Impact & Recovery: LCD Outlook for H2 2021

Blog

COVID 19 Impact Recovery Media Telecom and Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Sapporo Clinical Laboratory fiscal Q2 profit falls YOY

Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal second quarter ended Sept. 30 amounted to ¥42.22 per share, a decrease of 10.1% from ¥46.97 per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥146.9 million, a decrease of 21.4% from ¥186.9 million in the year-earlier period.

The normalized profit margin declined to 3.4% from 4.5% in the year-earlier period.

Total revenue climbed on an annual basis to ¥4.29 billion from ¥4.17 billion, and total operating expenses climbed from the prior-year period to ¥4.06 billion from ¥3.88 billion.

Reported net income decreased 18.1% on an annual basis to ¥149.0 million, or ¥42.83 per share, from ¥182.0 million, or ¥45.74 per share.

As of Nov. 13, US$1 was equivalent to ¥122.78.